Research ExplorerPublicationsAllogeneic hematopoietic cell transplantation for acute myel...

Allogeneic hematopoietic cell transplantation for acute myeloid leukemia with hyperdiploid complex karyotype

Standard

Allogeneic hematopoietic cell transplantation for acute myeloid leukemia with hyperdiploid complex karyotype. / Poiré, Xavier; Labopin, Myriam; Polge, Emmanuelle; Ganser, Arnold; Socié, Gérard; Gedde-Dahl, Tobias; Forcade, Edouard; Finke, Jürgen; Chalandon, Yves; Bulabois, Claude-Eric; Yakoub-Agha, Ibrahim; Aljurf, Mahmoud; Kröger, Nicolaus; Blau, Igor Wolfgang; Nagler, Arnon; Esteve, Jordi; Mohty, Mohamad.

In: BONE MARROW TRANSPL, Vol. 59, No. 2, 02.2024, p. 264-269.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Poiré, X, Labopin, M, Polge, E, Ganser, A, Socié, G, Gedde-Dahl, T, Forcade, E, Finke, J, Chalandon, Y, Bulabois, C-E, Yakoub-Agha, I, Aljurf, M, Kröger, N, Blau, IW, Nagler, A, Esteve, J & Mohty, M 2024, 'Allogeneic hematopoietic cell transplantation for acute myeloid leukemia with hyperdiploid complex karyotype', BONE MARROW TRANSPL, vol. 59, no. 2, pp. 264-269. https://doi.org/10.1038/s41409-023-02167-1

APA

Poiré, X., Labopin, M., Polge, E., Ganser, A., Socié, G., Gedde-Dahl, T., Forcade, E., Finke, J., Chalandon, Y., Bulabois, C-E., Yakoub-Agha, I., Aljurf, M., Kröger, N., Blau, I. W., Nagler, A., Esteve, J., & Mohty, M. (2024). Allogeneic hematopoietic cell transplantation for acute myeloid leukemia with hyperdiploid complex karyotype. BONE MARROW TRANSPL, 59(2), 264-269. https://doi.org/10.1038/s41409-023-02167-1

Vancouver

Poiré X, Labopin M, Polge E, Ganser A, Socié G, Gedde-Dahl T et al. Allogeneic hematopoietic cell transplantation for acute myeloid leukemia with hyperdiploid complex karyotype. BONE MARROW TRANSPL. 2024 Feb;59(2):264-269. https://doi.org/10.1038/s41409-023-02167-1

Bibtex

@article{8358fca486be49e5821718ff61bee485,
title = "Allogeneic hematopoietic cell transplantation for acute myeloid leukemia with hyperdiploid complex karyotype",
abstract = "Allogeneic hematopoietic cell transplantation (allo-HCT) remains the best consolidation strategy for acute myeloid leukemia (AML) with complex karyotype (CK). However, CK is a heterogenous and highly diverse entity. Numerical abnormalities have been associated with a controversial prognosis and AML with only multiple numerical abnormalities known as pure hyperdiploid karyotype (HDK) may have a distinct prognosis after allo-HCT compared to non-pure HDK CK AML. A total of 236 patients were identified within the EBMT registry as having HDK comprising 95 pure (pHDK) and 141 with other cytogenetic abnormalities (HDK+). The 2-year probability of leukemia-free survival (LFS) was 50% for pHDK and 31% for HDK+ (p = 0.003). The 2-year probability of overall survival (OS) was 57% for pHDK and 36% for HDK+ (p = 0.007). The 2-year cumulative incidence of relapse (RI) was 22% for pHDK and 44% for HDK+ (p = 0.001). The 2-year probability of graft-versus-host disease (GvHD)-free and relapse-free survival (GRFS) was 36% for pHDK and 21% for HDK+ (p = 0.01). On multivariate analysis, pHDK remained associated with significantly better LFS, OS and GRFS and lower RI (all p-values <0.004). pHDK AML constitutes probably a distinct cytogenetic entity from HDK+ or other non-hyperdiploid CK AML with better outcomes after allo-HCT.",
keywords = "Humans, Retrospective Studies, Hematopoietic Stem Cell Transplantation/adverse effects, Leukemia, Myeloid, Acute/genetics, Prognosis, Karyotype, Graft vs Host Disease/etiology, Recurrence, Transplantation Conditioning/adverse effects",
author = "Xavier Poir{\'e} and Myriam Labopin and Emmanuelle Polge and Arnold Ganser and G{\'e}rard Soci{\'e} and Tobias Gedde-Dahl and Edouard Forcade and J{\"u}rgen Finke and Yves Chalandon and Claude-Eric Bulabois and Ibrahim Yakoub-Agha and Mahmoud Aljurf and Nicolaus Kr{\"o}ger and Blau, {Igor Wolfgang} and Arnon Nagler and Jordi Esteve and Mohamad Mohty",
note = "{\textcopyright} 2023. The Author(s), under exclusive licence to Springer Nature Limited.",
year = "2024",
month = feb,
doi = "10.1038/s41409-023-02167-1",
language = "English",
volume = "59",
pages = "264--269",
journal = "BONE MARROW TRANSPL",
issn = "0268-3369",
publisher = "NATURE PUBLISHING GROUP",
number = "2",

}

RIS

TY - JOUR

T1 - Allogeneic hematopoietic cell transplantation for acute myeloid leukemia with hyperdiploid complex karyotype

AU - Poiré, Xavier

AU - Labopin, Myriam

AU - Polge, Emmanuelle

AU - Ganser, Arnold

AU - Socié, Gérard

AU - Gedde-Dahl, Tobias

AU - Forcade, Edouard

AU - Finke, Jürgen

AU - Chalandon, Yves

AU - Bulabois, Claude-Eric

AU - Yakoub-Agha, Ibrahim

AU - Aljurf, Mahmoud

AU - Kröger, Nicolaus

AU - Blau, Igor Wolfgang

AU - Nagler, Arnon

AU - Esteve, Jordi

AU - Mohty, Mohamad

N1 - © 2023. The Author(s), under exclusive licence to Springer Nature Limited.

PY - 2024/2

Y1 - 2024/2

N2 - Allogeneic hematopoietic cell transplantation (allo-HCT) remains the best consolidation strategy for acute myeloid leukemia (AML) with complex karyotype (CK). However, CK is a heterogenous and highly diverse entity. Numerical abnormalities have been associated with a controversial prognosis and AML with only multiple numerical abnormalities known as pure hyperdiploid karyotype (HDK) may have a distinct prognosis after allo-HCT compared to non-pure HDK CK AML. A total of 236 patients were identified within the EBMT registry as having HDK comprising 95 pure (pHDK) and 141 with other cytogenetic abnormalities (HDK+). The 2-year probability of leukemia-free survival (LFS) was 50% for pHDK and 31% for HDK+ (p = 0.003). The 2-year probability of overall survival (OS) was 57% for pHDK and 36% for HDK+ (p = 0.007). The 2-year cumulative incidence of relapse (RI) was 22% for pHDK and 44% for HDK+ (p = 0.001). The 2-year probability of graft-versus-host disease (GvHD)-free and relapse-free survival (GRFS) was 36% for pHDK and 21% for HDK+ (p = 0.01). On multivariate analysis, pHDK remained associated with significantly better LFS, OS and GRFS and lower RI (all p-values <0.004). pHDK AML constitutes probably a distinct cytogenetic entity from HDK+ or other non-hyperdiploid CK AML with better outcomes after allo-HCT.

AB - Allogeneic hematopoietic cell transplantation (allo-HCT) remains the best consolidation strategy for acute myeloid leukemia (AML) with complex karyotype (CK). However, CK is a heterogenous and highly diverse entity. Numerical abnormalities have been associated with a controversial prognosis and AML with only multiple numerical abnormalities known as pure hyperdiploid karyotype (HDK) may have a distinct prognosis after allo-HCT compared to non-pure HDK CK AML. A total of 236 patients were identified within the EBMT registry as having HDK comprising 95 pure (pHDK) and 141 with other cytogenetic abnormalities (HDK+). The 2-year probability of leukemia-free survival (LFS) was 50% for pHDK and 31% for HDK+ (p = 0.003). The 2-year probability of overall survival (OS) was 57% for pHDK and 36% for HDK+ (p = 0.007). The 2-year cumulative incidence of relapse (RI) was 22% for pHDK and 44% for HDK+ (p = 0.001). The 2-year probability of graft-versus-host disease (GvHD)-free and relapse-free survival (GRFS) was 36% for pHDK and 21% for HDK+ (p = 0.01). On multivariate analysis, pHDK remained associated with significantly better LFS, OS and GRFS and lower RI (all p-values <0.004). pHDK AML constitutes probably a distinct cytogenetic entity from HDK+ or other non-hyperdiploid CK AML with better outcomes after allo-HCT.

KW - Humans

KW - Retrospective Studies

KW - Hematopoietic Stem Cell Transplantation/adverse effects

KW - Leukemia, Myeloid, Acute/genetics

KW - Prognosis

KW - Karyotype

KW - Graft vs Host Disease/etiology

KW - Recurrence

KW - Transplantation Conditioning/adverse effects

U2 - 10.1038/s41409-023-02167-1

DO - 10.1038/s41409-023-02167-1

M3 - SCORING: Journal article

C2 - 38092959

VL - 59

SP - 264

EP - 269

JO - BONE MARROW TRANSPL

JF - BONE MARROW TRANSPL

SN - 0268-3369

IS - 2

ER -